OZEM.US Roundhill Glp-1 & Weight Loss ETF
- Total assets
- 58.2M
- Expense ratio
- 0.59%
- Dividend yield
- 1.33%
- 1-year return
- +3.77%
- Holdings
- 10
- Since
- 2024
Fund data as reported by the issuer, updated Nov 17, 2026. Total assets are in the fund's base currency.
What does OZEM.US invest in?
- Mostly Non-US stocks (53.7%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (43.9%)
- Top 3 holdings: 34.2% of the fund
Asset allocation
- Non-US stocks 53.7%
- US stocks 44.2%
- Other 1.2%
Top holdings
- Eli Lilly and Company 15.03%
- Novo Nordisk A/S 11.23%
- Pfizer Inc 7.90%
- Kailera Therapeutics, Inc. Common Stock 5.72%
- CSPC Pharmaceutical Group Ltd 5.26%
Roundhill Glp-1 & Weight Loss ETF performance
Sharpe ratio 0.00- This year
- -7.02%
- 1 year
- +3.77%
- 3 years
- -
- 5 years
- -
Volatility 20.6% over 1 year. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
OZEM.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Roundhill Glp-1 & Weight Loss ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
Full fund profileRoundhill Glp-1 & Weight Loss ETF top holdings
67.7% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Eli Lilly and Company LLY.US | Healthcare | United States | 15.03% |
| Novo Nordisk A/S NVO.US | Healthcare | United States | 11.23% |
| Pfizer Inc PFE.US | Healthcare | United States | 7.90% |
| Kailera Therapeutics, Inc. Common Stock KLRA.US | Healthcare | United States | 5.72% |
| CSPC Pharmaceutical Group Ltd 1093.HK | Healthcare | Hong Kong | 5.26% |
| Chugai Pharmaceutical Co. Ltd. 4519.TSE | Healthcare | Japan | 5.10% |
| Amgen Inc AMGN.US | Healthcare | United States | 4.70% |
| Viking Therapeutics Inc VKTX.US | Healthcare | United States | 4.64% |
| AstraZeneca PLC AZN.LSE | Healthcare | United Kingdom | 4.43% |
| Hanmi Pharm Co Ltd 128940.KQ | - | Korea | 3.69% |
OZEM.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
OZEM.US regional exposure
- North America43.9%
- Europe Developed26.5%
- Asia Emerging18.6%
- Japan4.6%
- Asia Developed3.9%
- United Kingdom3.3%
Share of the stocks in the fund.
Company size
Average market cap 55.7B- Mega cap46.2%
- Big cap29.3%
- Medium cap7.3%
- Small cap8.3%
- Micro cap9.3%
Roundhill Glp-1 & Weight Loss ETF fund profile
- Fund name
- Roundhill Glp-1 & Weight Loss ETF
- Ticker
- OZEM.US
- Exchange
- USA Stocks
- Issuer
- Roundhill Investments
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- May 20, 2024
- Trading currency
- USD
- Expense ratio
- 0.59%
About Roundhill Glp-1 & Weight Loss ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.